{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:33:16Z","timestamp":1788201196050,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12325-025-03272-x","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T13:19:55Z","timestamp":1752239995000},"page":"4486-4509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Safety and Effectiveness of Vadadustat in Patients with Chronic Kidney Disease-Related Anemia: Interim Analysis of Postmarketing Surveillance in Japan"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"umin000042349","registry":"10.18810\/umin-japan"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7401-2934","authenticated-orcid":false,"given":"Masaomi","family":"Nangaku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5267-8284","authenticated-orcid":false,"given":"Kazuyo","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0394-6638","authenticated-orcid":false,"given":"Jing","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3489-6971","authenticated-orcid":false,"given":"Kiichiro","family":"Ueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihoko","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"10","key":"3272_CR1","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/asn.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631\u20134. https:\/\/doi.org\/10.1681\/asn.2011111078.","journal-title":"J Am Soc Nephrol"},{"key":"3272_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/kisup.2012.33","volume":"2","author":"KDIGO","year":"2012","unstructured":"KDIGO.\u00a0 KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International Supplements. 2012;2:288\u2013291. https:\/\/doi.org\/10.1038\/kisup.2012.33.","journal-title":"Kidney International Supplements"},{"issue":"3","key":"3272_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000366025","volume":"40","author":"A Covic","year":"2014","unstructured":"Covic A, Nistor I, Donciu MD, Dumea R, Bolignano D, Goldsmith D. Erythropoiesis-stimulating agents (ESA) for preventing the progression of chronic kidney disease: a meta-analysis of 19 studies. Am J Nephrol. 2014;40(3):263\u201379. https:\/\/doi.org\/10.1159\/000366025.","journal-title":"Am J Nephrol"},{"issue":"3","key":"3272_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nrneph.2015.193","volume":"12","author":"PH Maxwell","year":"2016","unstructured":"Maxwell PH, Eckardt KU. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol. 2016;12(3):157\u201368. https:\/\/doi.org\/10.1038\/nrneph.2015.193.","journal-title":"Nat Rev Nephrol"},{"key":"3272_CR5","first-page":"711","volume":"62","author":"K Uchida","year":"2020","unstructured":"Uchida K, Nangaku M, Abe M, et al. The Japanese Society of Nephrology: recommendation on the appropriate use of HIF-PH inhibitors. Jpn J Nephrol. 2020;62:711\u20136 (in Japanese).","journal-title":"Jpn J Nephrol"},{"issue":"2","key":"3272_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/nep.13835","volume":"26","author":"DYH Yap","year":"2021","unstructured":"Yap DYH, McMahon LP, Hao CM, et al. Recommendations by the Asian Pacific Society of Nephrology (APSN) on the appropriate use of HIF-PH inhibitors. Nephrology (Carlton). 2021;26(2):105\u201318. https:\/\/doi.org\/10.1111\/nep.13835.","journal-title":"Nephrology (Carlton)"},{"issue":"7","key":"3272_CR7","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1681\/asn.2020091311","volume":"32","author":"M Nangaku","year":"2021","unstructured":"Nangaku M, Kondo K, Kokado Y, et al. Phase\u00a03 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. J Am Soc Nephrol. 2021;32(7):1779\u201390. https:\/\/doi.org\/10.1681\/asn.2020091311.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"3272_CR8","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/1744-9987.13611","volume":"25","author":"M Nangaku","year":"2021","unstructured":"Nangaku M, Kondo K, Takabe S, et al. Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: a phase\u00a03 open-label study in Japan. Ther Apher Dial. 2021;25(5):642\u201353. https:\/\/doi.org\/10.1111\/1744-9987.13611.","journal-title":"Ther Apher Dial"},{"issue":"9","key":"3272_CR9","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/ndt\/gfab055","volume":"36","author":"M Nangaku","year":"2021","unstructured":"Nangaku M, Kondo K, Ueta K, et al. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase\u00a03, multicenter, randomized, double-blind study. Nephrol Dial Transplant. 2021;36(9):1731\u201341. https:\/\/doi.org\/10.1093\/ndt\/gfab055.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"3272_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/1744-9987.13699","volume":"26","author":"M Nangaku","year":"2022","unstructured":"Nangaku M, Kondo K, Takabe S, et al. A phase\u00a03, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents. Ther Apher Dial. 2022;26(1):45\u201354. https:\/\/doi.org\/10.1111\/1744-9987.13699.","journal-title":"Ther Apher Dial"},{"key":"3272_CR11","unstructured":"Japan Society of Nephrology. Renal anemia. Evidence-based CKD treatment guidelines 2023; 2023. (in Japanese). https:\/\/cdn.jsn.or.jp\/medic\/guideline\/pdf\/guide\/viewer.html?file=001-294.pdf. Accessed 25 Feb 2025."},{"issue":"1","key":"3272_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s41100-017-0114-y","volume":"3","author":"H Yamamoto","year":"2017","unstructured":"Yamamoto H, Nishi S, Tomo T, et al. 2015 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ren Replace Ther. 2017;3(1):36. https:\/\/doi.org\/10.1186\/s41100-017-0114-y.","journal-title":"Ren Replace Ther"},{"key":"3272_CR13","unstructured":"Mitsubishi Tanabe Pharma Corporation, Vafseo\u00ae Tablets, Package insert (in Japanese). https:\/\/www.info.pmda.go.jp\/go\/pack\/3999050F1020_1_04\/. Accessed 25 Feb 2025."},{"issue":"6","key":"3272_CR14","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034.","journal-title":"Am J Kidney Dis"},{"key":"3272_CR15","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1038\/ki.2008.523","volume":"111","author":"JM L\u00f3pez-G\u00f3mez","year":"2008","unstructured":"L\u00f3pez-G\u00f3mez JM, Portol\u00e9s JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl. 2008;111:S75-81. https:\/\/doi.org\/10.1038\/ki.2008.523.","journal-title":"Kidney Int Suppl"},{"key":"3272_CR16","unstructured":"Mitsubishi Tanabe Pharma Corporation. Vafseo Tablets 150 mg, 300 mg (Section 2.7.4 Summary of Clinical Safety, Common Technical Document) (in Japanese). https:\/\/www.pmda.go.jp\/drugs\/2020\/P20200619002\/index.html. Accessed 25 Feb 2025."},{"key":"3272_CR17","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/ndt\/gfaa060","volume":"36","author":"M Nangaku","year":"2021","unstructured":"Nangaku M, Farag YMK, deGoma E, Luo W, Vargo D, Khawaja Z. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase\u00a02 trials in Japanese patients. Nephrol Dial Transplant. 2021;36:1244\u201352. https:\/\/doi.org\/10.1093\/ndt\/gfaa060.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"3272_CR18","first-page":"313","volume":"45","author":"T Akizawa","year":"2024","unstructured":"Akizawa T, Iimura S, Kanaya K, et al. Safety of daprodustat for the treatment of chronic kidney disease anemia. Ther Res. 2024;45(5):313\u201333.","journal-title":"Ther Res"},{"issue":"5","key":"3272_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10157-023-02432-z","volume":"28","author":"M Nangaku","year":"2024","unstructured":"Nangaku M, Ueta K, Nishimura K, Sasaki K, Hashimoto T. Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase\u00a03 randomized studies. Clin Exp Nephrol. 2024;28(5):391\u2013403. https:\/\/doi.org\/10.1007\/s10157-023-02432-z.","journal-title":"Clin Exp Nephrol"},{"issue":"9","key":"3272_CR20","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1159\/000519043","volume":"52","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Tanaka-Amino K, Otsuka T, Yamaguchi Y. Factors affecting doses of roxadustat versus darbepoetin alfa for anemia in nondialysis patients. Am J Nephrol. 2021;52(9):702\u201313. https:\/\/doi.org\/10.1159\/000519043.","journal-title":"Am J Nephrol"},{"issue":"5","key":"3272_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/1744-9987.13609","volume":"25","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Yamaguchi Y, Majikawa Y, Reusch M. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. Ther Apher Dial. 2021;25(5):575\u201385. https:\/\/doi.org\/10.1111\/1744-9987.13609.","journal-title":"Ther Apher Dial"},{"issue":"2","key":"3272_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1136\/hrt.2007.140905","volume":"95","author":"AJ Kerr","year":"2009","unstructured":"Kerr AJ, Broad J, Wells S, Riddell T, Jackson R. Should the first priority in cardiovascular risk management be those with prior cardiovascular disease? Heart. 2009;95(2):125\u20139. https:\/\/doi.org\/10.1136\/hrt.2007.140905.","journal-title":"Heart"},{"issue":"3","key":"3272_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","volume":"148","author":"GL Semenza","year":"2012","unstructured":"Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399\u2013408. https:\/\/doi.org\/10.1016\/j.cell.2012.01.021.","journal-title":"Cell"},{"key":"3272_CR24","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2024waw3fq0h","author":"GM Chertow","year":"2024","unstructured":"Chertow GM, Burke SK, Eckardt K-U, et al. Long-term safety of vadadustat for treatment of anemia-related CKD in phase\u00a03 trials: Conference poster TH-PO908. J Am Soc Nephrol. 2024. https:\/\/doi.org\/10.1681\/ASN.2024waw3fq0h.","journal-title":"J Am Soc Nephrol"},{"key":"3272_CR25","doi-asserted-by":"publisher","first-page":"1163908","DOI":"10.3389\/fphar.2023.1163908","volume":"14","author":"D Chen","year":"2023","unstructured":"Chen D, Niu Y, Liu F, et al. Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis. Front Pharmacol. 2023;14:1163908. https:\/\/doi.org\/10.3389\/fphar.2023.1163908.","journal-title":"Front Pharmacol"},{"issue":"3","key":"3272_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-023-00848-6","volume":"23","author":"X Yuan","year":"2024","unstructured":"Yuan X, Ruan W, Bobrow B, Carmeliet P, Eltzschig HK. Targeting hypoxia-inducible factors: therapeutic opportunities and challenges. Nat Rev Drug Discov. 2024;23(3):175\u2013200. https:\/\/doi.org\/10.1038\/s41573-023-00848-6.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"3272_CR27","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.kint.2018.06.008","volume":"94","author":"A Kraus","year":"2018","unstructured":"Kraus A, Peters DJM, Klanke B, et al. HIF-1\u03b1 promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease. Kidney Int. 2018;94(5):887\u201399. https:\/\/doi.org\/10.1016\/j.kint.2018.06.008.","journal-title":"Kidney Int"},{"key":"3272_CR28","unstructured":"Akebia Therapeutics, Vafseo\u00ae [Package Insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215192s000lbl.pdf. Accessed 25 Feb 2025."},{"issue":"10","key":"3272_CR29","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/ndt\/gfae075","volume":"39","author":"S Stoumpos","year":"2024","unstructured":"Stoumpos S, Crowe K, Sarafidis P, et al. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association. Nephrol Dial Transplant. 2024;39(10):1710\u201330. https:\/\/doi.org\/10.1093\/ndt\/gfae075.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"3272_CR30","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1210\/clinem\/dgad483","volume":"109","author":"T Haraguchi","year":"2023","unstructured":"Haraguchi T, Hamamoto Y, Kuwata H, et al. Effect of roxadustat on thyroid function in patients with renal anemia. J Clin Endocrinol Metab. 2023;109(1):e69\u201375. https:\/\/doi.org\/10.1210\/clinem\/dgad483.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"3272_CR31","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nrneph.2015.82","volume":"11","author":"MJ Koury","year":"2015","unstructured":"Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol. 2015;11(7):394\u2013410. https:\/\/doi.org\/10.1038\/nrneph.2015.82.","journal-title":"Nat Rev Nephrol"},{"issue":"32","key":"3272_CR32","doi-asserted-by":"publisher","first-page":"20055","DOI":"10.1074\/jbc.272.32.20055","volume":"272","author":"A Rolfs","year":"1997","unstructured":"Rolfs A, Kvietikova I, Gassmann M, Wenger RH. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem. 1997;272(32):20055\u201362. https:\/\/doi.org\/10.1074\/jbc.272.32.20055.","journal-title":"J Biol Chem"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03272-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03272-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03272-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:04:12Z","timestamp":1756371852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03272-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3272"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03272-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Masaomi Nangaku has received lecture fees from Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin, Astellas Pharma, AstraZeneca, GlaxoSmithKline, Daiichi Sankyo, Chugai Pharmaceutical, Torii Pharmaceutical, Japan Tobacco, Novo Nordisk Pharma, and Boehringer Ingelheim. MN has also received funding for commissioned research and joint research from Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin, Daiichi Sankyo, Astellas Pharma, Ono Pharmaceutical, Japan Tobacco, Chugai Pharmaceutical, Bayer, Torii Pharmaceutical, and Takeda Pharmaceuticals. Kazuyo Sasaki, Jing Bi, Kiichiro Ueta, Kenichi Nishimura, Takafumi Hashimoto and Mihoko Hata are employees of\u00a0Mitsubishi Tanabe Pharma Corporation .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The VIOLET survey was conducted by Mitsubishi Tanabe Pharma Corporation in compliance with the Japanese Ministerial Ordinance on GPSP, issued by the Japanese Ministry of Health, Labour and Welfare. GPSP guidelines do not require informed consent from patients or ethical approval from participating sites for PMS. The protocol for the VIOLET survey was approved by the Japanese Ministry of Health, Labour and Welfare. Patient data were collected anonymously. All participating patients provided written informed consent, which included an explanation of the purpose and procedures of the surveillance, confirmation that no additional costs would be incurred, the patient\u2019s right to decline participation, protection of personal information, publication and reporting of surveillance results to the Ministry of Health, Labour and Welfare in Japan, and the right to withdraw consent at any time.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}